FDA allows trial of controlled low-dose lenalidomide with Pfizer’s Elrexfio in multiple myeloma
An investigator-led U.S. trial will combine elranatamab with Starton Therapeutics’ investigational controlled low-dose lenalidomide in relapsed or refractory multiple myeloma.
